LinkedIn

 آمار

تعداد نشریات20
تعداد شماره‌ها1,149
تعداد مقالات10,518
تعداد مشاهده مقاله45,415,532
تعداد دریافت فایل اصل مقاله11,291,333
Keshavarzi, Fazlollah. (1401). Practical Concerns about the Metrics and Methods of Financial Outcome Measurement in Antimicrobial Stewardship Programs. سامانه مدیریت نشریات علمی, 47(5), 394-405. doi: 10.30476/ijms.2021.92213.2343
Fazlollah Keshavarzi. "Practical Concerns about the Metrics and Methods of Financial Outcome Measurement in Antimicrobial Stewardship Programs". سامانه مدیریت نشریات علمی, 47, 5, 1401, 394-405. doi: 10.30476/ijms.2021.92213.2343
Keshavarzi, Fazlollah. (1401). 'Practical Concerns about the Metrics and Methods of Financial Outcome Measurement in Antimicrobial Stewardship Programs', سامانه مدیریت نشریات علمی, 47(5), pp. 394-405. doi: 10.30476/ijms.2021.92213.2343
Keshavarzi, Fazlollah. Practical Concerns about the Metrics and Methods of Financial Outcome Measurement in Antimicrobial Stewardship Programs. سامانه مدیریت نشریات علمی, 1401; 47(5): 394-405. doi: 10.30476/ijms.2021.92213.2343

Practical Concerns about the Metrics and Methods of Financial Outcome Measurement in Antimicrobial Stewardship Programs

Iranian Journal of Medical Sciences
مقاله 2، دوره 47، شماره 5، آذر 2022، صفحه 394-405    اصل مقاله (286.82 K)
نوع مقاله: Review Article
شناسه دیجیتال (DOI): 10.30476/ijms.2021.92213.2343
نویسنده
Fazlollah Keshavarzi*
Department of Clinical Pharmacy, School of Pharmaceutical Sciences, UCSI University, Kuala Lumpur, Malaysia
چکیده
Emerging pathogens in the meantime of paucity of new antibiotics discovery, put antimicrobial stewardship in the center of attention, to preserve the existing antimicrobial effect. Implementation of antimicrobial stewardship programs, however, needs approval from healthcare system managers. The approval process can be enhanced, when the beneficial effects of stewardship programs are supported by both clinical and financial evidence. Focusing on the financial outcome evaluation, the practitioners who run the stewardship programs, may choose certain methods and metrics, depending on the clinical setting scale and type, available human resources, and budget. The wise selection of the methods and metrics warrants a comprehensive insight of the existing methods and metrics, deployed by typically published works that set good examples to follow. This review is an attempt to provide such an insight along with typical relevant examples for each metric and method. 
کلیدواژه‌ها
Anti-bacterial agents؛ Cost-benefit analysis؛ Health care economics and organizations؛ Antimicrobial stewardship
سایر فایل های مرتبط با مقاله
مراجع
  1. Brotherton AL. Metrics of Antimicrobial Stewardship Programs. Med Clin North Am. 2018;102:965-76. doi: 10.1016/j.mcna.2018.05.008. PubMed PMID: 30126585.
  2. Beardsley JR, Williamson JC, Johnson JW, Luther VP, Wrenn RH, Ohl CC. Show me the money: long-term financial impact of an antimicrobial stewardship program. Infect Control Hosp Epidemiol. 2012;33:398-400. doi: 10.1086/664922. PubMed PMID: 22418636.
  3. Barlam TF, Neuhauser MM, Tamma PD, Trivedi KK. Practical implementation of an antibiotic stewardship program. Cambridge: Cambridge University Press; 2018.
  4. Naylor NR, Zhu N, Hulscher M, Holmes A, Ahmad R, Robotham JV. Is antimicrobial stewardship cost-effective? A narrative review of the evidence. Clin Microbiol Infect. 2017;23:806-11. doi: 10.1016/j.cmi.2017.06.011. PubMed PMID: 28642146.
  5. Morgan AK, Awafo BA, Quartey T. The effects of COVID-19 on global economic output and sustainability: evidence from around the world and lessons for redress. Sustainability: Science, Practice and Policy. 2021;17:77-81. doi: 10.1080/15487733.2020.1860345.
  6. Pakyz AL, Oinonen M, Polk RE. Relationship of carbapenem restriction in 22 university teaching hospitals to carbapenem use and carbapenem-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2009;53:1983-6. doi: 10.1128/AAC.01535-08. PubMed PMID: 19273670; PubMed Central PMCID: PMCPMC2681502.
  7. Lima AL, Oliveira PR, Paula AP, Dal-Paz K, Almeida JN, Jr., Felix Cda S, et al. Carbapenem stewardship: positive impact on hospital ecology. Braz J Infect Dis. 2011;15:1-5. doi: 10.1016/s1413-8670(11)70131-3. PubMed PMID: 21412581.
  8. Ahmad F, Pogue JM, Marchaim D, Chopra T, Bheemreddy S, Lee J, et al. Evaluation of the potential impact of a carbapenem de-escalation program in an academic healthcare system. J Infect Public Health. 2014;7:50-3. doi: 10.1016/j.jiph.2013.09.004. PubMed PMID: 24210246.
  9. Yoon YK, Yang KS, Lee SE, Kim HJ, Sohn JW, Kim MJ. Effects of Group 1 versus Group 2 carbapenems on the susceptibility of Acinetobacter baumannii to carbapenems: a before and after intervention study of carbapenem-use stewardship. PLoS One. 2014;9:e99101. doi: 10.1371/journal.pone.0099101. PubMed PMID: 24911244; PubMed Central PMCID: PMCPMC4049602.
  10. Viale P, Tumietto F, Giannella M, Bartoletti M, Tedeschi S, Ambretti S, et al. Impact of a hospital-wide multifaceted programme for reducing carbapenem-resistant Enterobacteriaceae infections in a large teaching hospital in northern Italy. Clin Microbiol Infect. 2015;21:242-7. doi: 10.1016/j.cmi.2014.10.020. PubMed PMID: 25658534.
  11. Pérez Serrano R, Martín Siguero A, Porras Leal M, Castón Osorio J, González Gasca F, Abdelhadi Álvarez H, et al. CP-132 Impact of implementing a carbapenem stewardship program. European Journal of Hospital Pharmacy. 2015;22:A53. doi: 10.1136/ejhpharm-2015-000639.126.
  12. Tagashira Y, Horiuchi M, Tokuda Y, Heist BS, Higuchi M, Honda H. Antimicrobial stewardship for carbapenem use at a Japanese tertiary care center: An interrupted time series analysis on the impact of infectious disease consultation, prospective audit, and feedback. Am J Infect Control. 2016;44:708-10. doi: 10.1016/j.ajic.2015.12.016. PubMed PMID: 26831278.
  13. Delgado A, Lee GC, Gawrys GW, Duhon BM, Koeller JM. Impact of an Antimicrobial Stewardship Initiative on Ertapenem Use and Carbapenem Susceptibilities at Four Community Hospitals. Open Forum Infectious Diseases. 2015;2. doi: 10.1093/ofid/ofv133.1004.
  14. Seah VXF, Ong RYL, Lim ASY, Chong CY, Tan NWH, Thoon KC. Impact of a Carbapenem Antimicrobial Stewardship Program on Patient Outcomes. Antimicrob Agents Chemother. 2017;61. doi: 10.1128/AAC.00736-17. PubMed PMID: 28717037; PubMed Central PMCID: PMCPMC5571328.
  15. Hwang H, Kim B. Impact of an infectious diseases specialist-led antimicrobial stewardship programmes on antibiotic use and antimicrobial resistance in a large Korean hospital. Sci Rep. 2018;8:14757. doi: 10.1038/s41598-018-33201-8. PubMed PMID: 30283084; PubMed Central PMCID: PMCPMC6170479.
  16. Zhang D, Cui K, Lu W, Bai H, Zhai Y, Hu S, et al. Evaluation of carbapenem use in a tertiary hospital: antimicrobial stewardship urgently needed. Antimicrob Resist Infect Control. 2019;8:5. doi: 10.1186/s13756-018-0449-3. PubMed PMID: 30627429; PubMed Central PMCID: PMCPMC6322243.
  17. Johnk SR, Grindeland CJ, Leedahl DD, Carson PJ, Leedahl ND. Impact of a multicenter stewardship-targeted carbapenem justification requirement on the use of carbapenems in 23 hospitals. Journal of the American College of Clinical Pharmacy. 2019;2:53-7. doi: 10.1002/jac5.1021.
  18. Ruttimann S, Keck B, Hartmeier C, Maetzel A, Bucher HC. Long-term antibiotic cost savings from a comprehensive intervention program in a medical department of a university-affiliated teaching hospital. Clin Infect Dis. 2004;38:348-56. doi: 10.1086/380964. PubMed PMID: 14727204.
  19. Sick AC, Lehmann CU, Tamma PD, Lee CK, Agwu AL. Sustained savings from a longitudinal cost analysis of an internet-based preapproval antimicrobial stewardship program. Infect Control Hosp Epidemiol. 2013;34:573-80. doi: 10.1086/670625. PubMed PMID: 23651887.
  20. Ansari F, Gray K, Nathwani D, Phillips G, Ogston S, Ramsay C, et al. Outcomes of an intervention to improve hospital antibiotic prescribing: interrupted time series with segmented regression analysis. J Antimicrob Chemother. 2003;52:842-8. doi: 10.1093/jac/dkg459. PubMed PMID: 14563900.
  21. Gums JG, Yancey RW, Jr., Hamilton CA, Kubilis PS. A randomized, prospective study measuring outcomes after antibiotic therapy intervention by a multidisciplinary consult team. Pharmacotherapy. 1999;19:1369-77. doi: 10.1592/phco.19.18.1369.30898. PubMed PMID: 10600085.
  22. Scheetz MH, Bolon MK, Postelnick M, Noskin GA, Lee TA. Cost-effectiveness analysis of an antimicrobial stewardship team on bloodstream infections: a probabilistic analysis. J Antimicrob Chemother. 2009;63:816-25. doi: 10.1093/jac/dkp004. PubMed PMID: 19202150.
  23. Hamblin S, Rumbaugh K, Miller R. Prevention of adverse drug events and cost savings associated with PharmD interventions in an academic Level I trauma center: an evidence-based approach. J Trauma Acute Care Surg. 2012;73:1484-90. doi: 10.1097/TA.0b013e318267cd80. PubMed PMID: 23064610.
  24. Lin YS, Lin IF, Yen YF, Lin PC, Shiu YC, Hu HY, et al. Impact of an antimicrobial stewardship program with multidisciplinary cooperation in a community public teaching hospital in Taiwan. Am J Infect Control. 2013;41:1069-72. doi: 10.1016/j.ajic.2013.04.004. PubMed PMID: 23870295.
  25. Garcia-Rodriguez JF, Bardan-Garcia B, Pena-Rodriguez MF, Alvarez-Diaz H, Marino-Callejo A. Meropenem antimicrobial stewardship program: clinical, economic, and antibiotic resistance impact. Eur J Clin Microbiol Infect Dis. 2019;38:161-70. doi: 10.1007/s10096-018-3408-2. PubMed PMID: 30367313.
  26. Delory T, De Pontfarcy A, Emirian A, About F, Berdougo B, Brun-Buisson C, et al. Impact of a program combining pre-authorization requirement and post-prescription review of carbapenems: an interrupted time-series analysis. Eur J Clin Microbiol Infect Dis. 2013;32:1599-604. doi: 10.1007/s10096-013-1918-5. PubMed PMID: 23839593.
  27. Mouwen AMA, Dijkstra JA, Jong E, Buijtels P, Pasker-de Jong PCM, Nagtegaal JE. Early switching of antibiotic therapy from intravenous to oral using a combination of education, pocket-sized cards and switch advice: A practical intervention resulting in reduced length of hospital stay. Int J Antimicrob Agents. 2020;55:105769. doi: 10.1016/j.ijantimicag.2019.07.020. PubMed PMID: 31362046.
  28. Niwa T, Shinoda Y, Suzuki A, Ohmori T, Yasuda M, Ohta H, et al. Outcome measurement of extensive implementation of antimicrobial stewardship in patients receiving intravenous antibiotics in a Japanese university hospital. Int J Clin Pract. 2012;66:999-1008. doi: 10.1111/j.1742-1241.2012.02999.x. PubMed PMID: 22846073; PubMed Central PMCID: PMCPMC3469737.
  29. Chandrasekhar D, PokkaVayalil V. Cost minimization analysis on IV to oral conversion of antimicrobial agent by the clinical pharmacist intervention. Clinical Epidemiology and Global Health. 2019;7:60-5. doi: 10.1016/j.cegh.2018.01.001.
  30. Dik JW, Hendrix R, Friedrich AW, Luttjeboer J, Panday PN, Wilting KR, et al. Cost-minimization model of a multidisciplinary antibiotic stewardship team based on a successful implementation on a urology ward of an academic hospital. PLoS One. 2015;10:e0126106. doi: 10.1371/journal.pone.0126106. PubMed PMID: 25955494; PubMed Central PMCID: PMCPMC4425554.
  31. Slayton RB, Scott RD, Baggs J, Lessa FC, McDonald LC, Jernigan JA. The cost-benefit of federal investment in preventing Clostridium difficile infections through the use of a multifaceted infection control and antimicrobial stewardship program. Infect Control Hosp Epidemiol. 2015;36:681-7. doi: 10.1017/ice.2015.43. PubMed PMID: 25783204; PubMed Central PMCID: PMCPMC6550306.
  32. Bhavnani SM, Ambrose PG. Cost-effectiveness of oral gemifloxacin versus intravenous ceftriaxone followed by oral cefuroxime with/without a macrolide for the treatment of hospitalized patients with community-acquired pneumonia. Diagn Microbiol Infect Dis. 2008;60:59-64. doi: 10.1016/j.diagmicrobio.2007.07.006. PubMed PMID: 17889491.
  33. Collins CD, Brockhaus K, Sim T, Suneja A, Malani AN. Analysis to determine cost-effectiveness of procalcitonin-guided antibiotic use in adult patients with suspected bacterial infection and sepsis. Am J Health Syst Pharm. 2019;76:1219-25. doi: 10.1093/ajhp/zxz129. PubMed PMID: 31369118.
  34. McKinnell JA, Corman S, Patel D, Leung GH, Gordon LM, Lodise TP. Effective Antimicrobial Stewardship Strategies for Cost-effective Utilization of Telavancin for the Treatment of Patients With Hospital-acquired Bacterial Pneumonia Caused by Staphylococcus aureus. Clin Ther. 2018;40:406-14 e2. doi: 10.1016/j.clinthera.2018.01.010. PubMed PMID: 29454592.
  35. Okumura LM, Riveros BS, Gomes-da-Silva MM, Veroneze I. A cost-effectiveness analysis of two different antimicrobial stewardship programs. Braz J Infect Dis. 2016;20:255-61. doi: 10.1016/j.bjid.2016.02.005. PubMed PMID: 27094234.
  36. Ruiz-Ramos J, Frasquet J, Roma E, Poveda-Andres JL, Salavert-Leti M, Castellanos A, et al. Cost-effectiveness analysis of implementing an antimicrobial stewardship program in critical care units. J Med Econ. 2017;20:652-9. doi: 10.1080/13696998.2017.1311903. PubMed PMID: 28345481.
  37. Voermans AM, Mewes JC, Broyles MR, Steuten LMG. Cost-Effectiveness Analysis of a Procalcitonin-Guided Decision Algorithm for Antibiotic Stewardship Using Real-World U.S. Hospital Data. OMICS. 2019;23:508-15. doi: 10.1089/omi.2019.0113. PubMed PMID: 31509068; PubMed Central PMCID: PMCPMC6806362.
  38. So M, Mamdani MM, Morris AM, Lau TTY, Broady R, Deotare U, et al. Effect of an antimicrobial stewardship programme on antimicrobial utilisation and costs in patients with leukaemia: a retrospective controlled study. Clin Microbiol Infect. 2018;24:882-8. doi: 10.1016/j.cmi.2017.11.009. PubMed PMID: 29138099.
  39. Gutierrez-Urbon JM, Gil-Navarro MV, Moreno-Ramos F, Nunez-Nunez M, Pano-Pardo JR, Perianez-Parraga L. Indicators of the hospital use of antimicrobial agents based on consumption. Farm Hosp. 2019;43:94-100. doi: 10.7399/fh.11163. PubMed PMID: 31072287.
  40. Thabit AK, Shea KM, Guzman OE, Garey KW. Antibiotic utilization within 18 community hospitals in the United States: A 5-year analysis. Pharmacoepidemiol Drug Saf. 2021;30:403-8. doi: 10.1002/pds.5156. PubMed PMID: 33094502.
  41. Xiao Y, Shen P, Zheng B, Zhou K, Luo Q, Li L. Change in Antibiotic Use in Secondary and Tertiary Hospitals Nationwide After a National Antimicrobial Stewardship Campaign Was Launched in China, 2011-2016: An Observational Study. J Infect Dis. 2020;221:S148-S55. doi: 10.1093/infdis/jiz556. PubMed PMID: 32176788.
  42. Jover-Saenz A, Ramirez-Hidalgo MF, Vidal MV, Gonzalez MG, Cano Marron SM, Arias AE, et al. Antimicrobial stewardship program at a tertiary care academic medical hospital: Clinical, microbiological and economic impact. A 5-year temporary descriptive study. Infect Prev Pract. 2020;2:100048. doi: 10.1016/j.infpip.2020.100048. PubMed PMID: 34368698; PubMed Central PMCID: PMCPMC8335906.
  43. Mewes JC, Pulia MS, Mansour MK, Broyles MR, Nguyen HB, Steuten LM. The cost impact of PCT-guided antibiotic stewardship versus usual care for hospitalised patients with suspected sepsis or lower respiratory tract infections in the US: A health economic model analysis. PLoS One. 2019;14:e0214222. doi: 10.1371/journal.pone.0214222. PubMed PMID: 31013271; PubMed Central PMCID: PMCPMC6478294.
  44. Stocker H, Mehlhorn C, Jordan K, Eckholt L, Jefferys L, Arasteh K. Clinical and economic effects of an antimicrobial stewardship intervention in a surgical intensive care unit. Infection. 2020;48:509-19. doi: 10.1007/s15010-020-01421-8. PubMed PMID: 32277409.
  45. Onorato L, Macera M, Calo F, Monari C, Russo F, Iovene MR, et al. The effect of an antimicrobial stewardship programme in two intensive care units of a teaching hospital: an interrupted time series analysis. Clin Microbiol Infect. 2020;26:782. doi: 10.1016/j.cmi.2019.10.021. PubMed PMID: 31678230.
  46. Penalva G, Fernandez-Urrusuno R, Turmo JM, Hernandez-Soto R, Pajares I, Carrion L, et al. Long-term impact of an educational antimicrobial stewardship programme in primary care on infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in the community: an interrupted time-series analysis. Lancet Infect Dis. 2020;20:199-207. doi: 10.1016/S1473-3099(19)30573-0. PubMed PMID: 31767423.
  47. Scott RD, 2nd, Slayton RB, Lessa FC, Baggs J, Culler SD, McDonald LC, et al. Assessing the social cost and benefits of a national requirement establishing antibiotic stewardship programs to prevent Clostridioides difficile infection in US hospitals. Antimicrob Resist Infect Control. 2019;8:17. doi: 10.1186/s13756-018-0459-1. PubMed PMID: 30680153; PubMed Central PMCID: PMCPMC6343309.
  48. Vazin A, Karimzadeh I, Karamikhah R, Oveisi Z, Mohseni S, Keykhaee M, et al. Clinical and economical impacts of guideline implementation by the pharmaceutical care unit for high cost medications in a referral teaching hospital. BMC Health Serv Res. 2018;18:815. doi: 10.1186/s12913-018-3627-3. PubMed PMID: 30355286; PubMed Central PMCID: PMCPMC6201544.
  49. Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford: Oxford university press; 2015.
  50. Haley RW. Measuring the costs of nosocomial infections: methods for estimating economic burden on the hospital. Am J Med. 1991;91:32S-8S. doi: 10.1016/0002-9343(91)90341-t. PubMed PMID: 1928186.
  51. Howard D, Cordell R, McGowan JE, Jr., Packard RM, Scott RD, 2nd, Solomon SL, et al. Measuring the economic costs of antimicrobial resistance in hospital settings: summary of the Centers for Disease Control and Prevention-Emory Workshop. Clin Infect Dis. 2001;33:1573-8. doi: 10.1086/323758. PubMed PMID: 11577379.
  52. Bennett N, Schulz L, Boyd S, Newland JG. Understanding inpatient antimicrobial stewardship metrics. Am J Health Syst Pharm. 2018;75:230-8. doi: 10.2146/ajhp160335. PubMed PMID: 29436469.
  53. Johannsson B, Beekmann SE, Srinivasan A, Hersh AL, Laxminarayan R, Polgreen PM. Improving antimicrobial stewardship: the evolution of programmatic strategies and barriers. Infect Control Hosp Epidemiol. 2011;32:367-74. doi: 10.1086/658946. PubMed PMID: 21460488.
  54. Nathwani D, Varghese D, Stephens J, Ansari W, Martin S, Charbonneau C. Value of hospital antimicrobial stewardship programs [ASPs]: a systematic review. Antimicrob Resist Infect Control. 2019;8:35. doi: 10.1186/s13756-019-0471-0. PubMed PMID: 30805182; PubMed Central PMCID: PMCPMC6373132.
  55. Wilson JP, Rascati KL. Pharmacoeconomics. In: Malone PM, editors. Drug Information A Guide for Pharmacists. Fifth ed. New York: McGraw-Hill Education; 2014.
  56. Roberts RR, Hota B, Ahmad I, Scott RD, 2nd, Foster SD, Abbasi F, et al. Hospital and societal costs of antimicrobial-resistant infections in a Chicago teaching hospital: implications for antibiotic stewardship. Clin Infect Dis. 2009;49:1175-84. doi: 10.1086/605630. PubMed PMID: 19739972.
  57. Michaelidis CI, Fine MJ, Lin CJ, Linder JA, Nowalk MP, Shields RK, et al. The hidden societal cost of antibiotic resistance per antibiotic prescribed in the United States: an exploratory analysis. BMC Infect Dis. 2016;16:655. doi: 10.1186/s12879-016-1990-4. PubMed PMID: 27825306; PubMed Central PMCID: PMCPMC5101711.
  58. WHO Collaborating Centre for Drug Statistics Methodology [Internet]. Guidelines for ATC classification and DDD assignment. c2014. Available from: https://www.whocc.no/atc_ddd_index.
  59. Hutchinson JM, Patrick DM, Marra F, Ng H, Bowie WR, Heule L, et al. Measurement of antibiotic consumption: A practical guide to the use of the Anatomical Thgerapeutic Chemical classification and Definied Daily Dose system methodology in Canada. Can J Infect Dis. 2004;15:29-35. doi: 10.1155/2004/389092. PubMed PMID: 18159441; PubMed Central PMCID: PMCPMC2094921.
  60. Strom BL. Pharmacoepidemiology. University of Pennsylvania. Philadelphia: John Wiley & Sons, Ltd; 2005.
  61. Dahlui M, Wan NC, Koon TS. Cost analysis of UMMC services: estimating the unit cost for outpatient and inpatient services. BMC Health Services Research. 2012;12:1-2. doi: 10.1186/1472-6963-12-S1-O1.
  62. Advani P, Alves J, Bekele B, Bentley F, Norris D, Patel R, et al. TrendWatch Chartbook 2016. Chicago: American Hospital Association; 2016.
  63. Taheri PA, Butz DA, Greenfield LJ. Length of stay has minimal impact on the cost of hospital admission. J Am Coll Surg. 2000;191:123-30. doi: 10.1016/s1072-7515(00)00352-5. PubMed PMID: 10945354.
  64. Lanbeck P, Ragnarson Tennvall G, Resman F. A cost analysis of introducing an infectious disease specialist-guided antimicrobial stewardship in an area with relatively low prevalence of antimicrobial resistance. BMC Health Serv Res. 2016;16:311. doi: 10.1186/s12913-016-1565-5. PubMed PMID: 27464508; PubMed Central PMCID: PMCPMC4963928.
  65. Horn SD, Horn RA, Sharkey PD. The Severity of Illness Index as a severity adjustment to diagnosis-related groups. Health Care Financ Rev. 1984;Suppl:33-45. PubMed PMID: 10311075; PubMed Central PMCID: PMCPMC4195109.
  66. Morris AM. Antimicrobial Stewardship Programs: Appropriate Measures and Metrics to Study their Impact. Curr Treat Options Infect Dis. 2014;6:101-12. doi: 10.1007/s40506-014-0015-3. PubMed PMID: 25999798; PubMed Central PMCID: PMCPMC4431704.
  67. Coulter S, Merollini K, Roberts JA, Graves N, Halton K. The need for cost-effectiveness analyses of antimicrobial stewardship programmes: A structured review. Int J Antimicrob Agents. 2015;46:140-9. doi: 10.1016/j.ijantimicag.2015.04.007. PubMed PMID: 26058776.
  68. You J. Antimicrobial stewardship programs - cost-minimizing or cost-effective? Expert Opin Pharmacother. 2015;16:155-7. doi: 10.1517/14656566.2015.973854. PubMed PMID: 25331093.
آمار
تعداد مشاهده مقاله: 16,324
تعداد دریافت فایل اصل مقاله: 3,975


سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب